Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Celltrion just completed the phase 3 trial for its COVID-19 antibody treatment and it has shown very positive results. The biopharmaceutical company headquartered in Incheon, South Korea proves the efficacy of its treatment and full phase 3 results will follow before this month ends.
Outcome of phase 3 tests for the new COVID-19 antibody treatment
Celltrion said on Monday, June 14, that phase 3 of the clinical study for its Rekirona, yielded good results. This means that it was proven to be safe and effective after being tested with volunteer patients from 13 countries worldwide.
As per The Korea Herald, 1,315 patients took part in the third phase trial for Rekirona or CT-P59. The tests were conducted between the months of January and April of this year.
The South Korean biotech company stated that the treatment is effective and significantly reduced the recovery time and rate of progression for acute symptoms of COVID-19. Celltrion discovered through the phase 3 trial that the risk of cases progressing to a severe condition of coronavirus infection was reduced by 70%. In the high-risk group of patients, the progression rate to severe stage was said to have been cut by 72%.
What’s more, those treated with Celltrion’s Rekirona also showed significant results in recovery time as it was shortened. It was said that recovering from the disease was 4.7 to 4.9 days faster compared to others who used other treatments, Yonhap News Agency reported.
Most importantly, it was reported that the Celltrion COVID-19 antibody treatment did not show any serious adverse reaction. Only mild and temporary reactions were noted on the patients during the trial.
Celltrion’s shares surge after Celltrion’s phase 3 trial results were announced
Meanwhile, Pulse News reported that Celltrion’s shares increased by 5.08 percent to ₩279,000 or around $249.69 after the phase 3 test results for Rekirona were revealed. Celltrion Pharm, the company’s drug developing unit’s shares also went up by 12.54 percent to ₩156,200 while Celltrion Healthcare’s shares surged to 5.02 percent to ₩123,500.
In any case, Celltrion will now use the good results to seek marketing approval for the Covid-19 therapy in the U.S. The company will submit the documents to the U.S. Food and Drug Administration and the European Medicines Agency so it can be allowed to sell the treatment in the said regions.
